Advertising disclosure: We earn commissions from some of the products we link to. It never changes our scores or what we publish. Read the full disclosure
PlexusDx
A compounded platform selling microdose, injectable and oral GLP-1s at flat per-compound rates — $129 a month for the microdose protocol, $149 to $189 for semaglutide and $249 to $289 for tirzepatide depending on commitment length — with the price stated to stay the same at every dose within a compound. It publishes a comparison table naming competitors and their rates. It also sells a $99 genetic test marketed as predicting GLP-1 response.
Sources captured · researched by Tom
As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.
PlexusDx publishes 7 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers
These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.
Someone who wants the price published before the intake and flat across doses, and who is comfortable skipping the genetic add-on.
Be sceptical. PlexusDx markets it as analysing 34 weight-management insights including GIPR rs1800437, a variant it describes as associated with differential GLP-1 response, from a CLIA-certified lab. CLIA certification means the laboratory meets a quality standard for running the test — it is not evidence that the result should change your treatment. Pharmacogenomic testing is not part of standard practice for prescribing or dosing GLP-1 medication, and no guideline recommends it. Before paying, ask the prescribing provider a direct question: would any result on this panel change my prescription or my dose? If the answer is no, you are buying information, not care.
Your price stays the same as your dose is titrated within a compound — so a semaglutide patient at $189 a month pays $189 whether at a starting or a high dose. It changes for two published reasons: choosing a longer commitment tier, which lowers it to $169 or $149, or switching compound entirely, for example from semaglutide to tirzepatide, which the provider initiates and which re-prices to the new compound's published rate with no switching fee.
Better than most. The page names competitors with their published rates and flags real distinctions — that one competitor's tirzepatide is an oral dissolving tablet rather than an injection and therefore not price-comparable, and that another's low headline is medication-only with a required membership on top. Those are the exact traps that make this market hard to compare. It is still a page written to sell you PlexusDx, so verify the figures at the source before relying on them.
Captured . Pages change — check the current version before relying on anything here.
Cora Health, with clinical services delivered through the Wasef Health provider network
Names both of its compounding pharmacies and publishes the whole price ladder, not a 'starting at' figure
TeleDocs360 LLC, a platform providing administrative and support services, with medical care provided by physicians affiliated with Impact Health, an independent physician network
Names the exact doses where the price rises, and will not raise it without your written confirmation first
Coby Health LLC, described as operating a marketplace and patient management system rather than providing medical or pharmacy services itself
Pay-as-you-go compounded GLP-1s with a published dose-by-dose price ladder and no subscription